Drugs / ABT450r
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02734173 Comparator | Jul 2015 → Feb 2017 | hepatitis C virus infection | Ottawa Hospital Research Institute | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT450r | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02734173 ↗ |
| Action | Inhibit | “a HCV protease inhibitor (ABT-450 based with ritonavir)” NCT02734173 ↗ |
| Route | Oral | “IFN-free, oral DAA regimens” NCT02734173 ↗ |